KPMG is a proud sponsor of the 16th Annual Personalized Medicine Conference. We will have strategy thought leaders available to speak with conference attendees. In the complex and fast-moving Precision Medicines market, KPMG can provide deep scientific, technical, and business insights at a local and global level. The KPMG Precision Medicine strategy practice is a leader in this innovative area of medicine across all therapeutic areas, with all relevant stakeholders, and fueled by experience across the value chain.
We encourage you to read our latest case studies and thought leadership
Our strategy practice is global, delivering solutions informed by our industry depth and local market knowledge.
Defining an organizational and capabilities roadmap for future market leadership for an oncology medical affairs team in a global biopharma client.
Developing a diagnostics strategy to support EMEA launch and commercialization of a global biopharma’s targeted first-in-class oncology asset.
The client, a CAR-T therapy manufacturer, identified the need to improve their cross-functional operating model to ensure sustainable supply and supply chain resiliency.
Conducting a detailed assessment of the current and future treatment paradigm in multiple myeloma for a leading biopharma client to assist with future market positioning.
As the world emerges into a "new normal" across life sciences due to the COVID-19 pandemic, we are entering a new phase of Precision Medicine (PM). Whether you are a medical institution developing personalized and holistic services for your patients in all therapeutic areas, the field of Precision Medicine has changed for everyone.
We are in a new era of scientific innovation where “one-and-done” gene therapies can potentially cure disease. However, headwinds still exist that will limit their use to rare and ultra-rare monogenic diseases for the next 5-10 years.